EMEA-001882-PIP02-16-M01

Key facts

Active substance
Recombinant human monoclonal antibody to GM-CSF (GSK3196165)
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0287/2019
PIP number
EMEA-001882-PIP02-16-M01
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)
Route(s) of administration
Subcutaneous use
Contact for public enquiries
GlaxoSmithKline Trading Services Limited

Tel. +44 2089903650
E-mail: eu.paediatric-plans@gsk.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating